Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals
- PMID: 17635694
- DOI: 10.1111/j.1743-6109.2007.00556.x
Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals
Abstract
Aim: Testosterone treatment is essential for the induction and maintenance of virilization of female-to-male transsexuals. This study tested the suitability of a novel testosterone preparation for this purpose.
Methods: Parenteral long-acting testosterone undecanoate (TU) was administered to 12 female-to-male transsexuals. Observations were made while subjects received treatment.
Main outcome measures: Virilization of female-to-male transsexuals and side effects of testosterone administration.
Results: The testosterone levels were largely identical to those in hypogonadal men receiving testosterone treatment with TU. There were no side effects. There was a small but significant decrease in plasma cholesterol and low-density lipoprotein, but plasma high-density lipoprotein did not change significantly. Both levels of hemoglobin and hematocrit rose upon administration but remained within the physiological range.
Conclusions: TU is suited for induction of virilization in female-to-male transsexuals without significant side effects.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
